Comparing two first-line treatments for newly diagnosed chronic myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two oral medications, flumatinib and imatinib, to see which is more effective and safer for people newly diagnosed with chronic myeloid leukemia in its early phase. It aims to help doctors choose the best initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with chronic myeloid leukemia (CML) in the chronic phase within the last 6 months.
- You have not previously taken any tyrosine kinase inhibitor (TKI) medications for CML.
- You have not had more than 2 weeks of other CML treatments or a stem cell transplant.
- You are not pregnant or breastfeeding.
- You have not participated in other clinical trials that could affect this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with chronic myeloid leukemia (CML) whose disease is resistant to or intolerant of current standard drugs. The goal is to see if the study drug works better when combined with another drug, and to check its safety.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This study compares two different medicines for people with chronic myeloid leukemia (CML) whose current treatment with imatinib (Gleevec) has not worked well enough. It tests whether switching to dasatinib (Sprycel) or increasing the dose of imatinib to 600 mg helps get the disease under better control.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This study tests clifutinib (a targeted medicine) combined with chemotherapy in people newly diagnosed with AML. It aims to see if this combination is safer and more effective, including in older adults and people who may not tolerate strong chemotherapy.
Hear when a new CML, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.